 |
|
|
|
Equip FT for the vaccination of healthy horses against equine influenza and tetanus.
An aqueous ISCOM (Immune Stimulating Complex) influenza vaccine plus concentrated immunopurified tetanus toxoid vaccine, for intramuscular injection. Each 2ml dose of the vaccine contains the inactivated antigens:
Influenza A/Equi 1/Newmarket 77 - 10 micrograms
Influenza A/Equi 2/Kentucky 98 - 1.4 micrograms
Influenza A/Equi 2/Borlange 91 - 20 micrograms
Immunopurified tetanus toxoid
adsorbed on to aluminium phosphate - 100 Lf units
|
|
Presentation
An aqueous ISCOM (Immune Stimulating Complex) influenza vaccine plus concentrated immunopurified tetanus toxoid vaccine, for intramuscular injection. Each 2ml dose of the vaccine contains the inactivated antigens:
Influenza A/Equi 1/Newmarket 77 - 10 micrograms
Influenza A/Equi 2/Kentucky 98 - 1.4 micrograms
Influenza A/Equi 2/Borlange 91 - 20 micrograms
Immunopurified tetanus toxoid
adsorbed on to aluminium phosphate - 100 Lf units
Uses
For the vaccination of healthy horses against equine influenza and tetanus.
|
|
Dosage and administration
Dose
2 ml
Administration
Equip FT should be shaken thoroughly before use and administered by deep intramuscular injection.
Vaccination Regime:
To provide protection against influenza and tetanus Equip FT should be used as follows:
Primary course ⎧
⎨
⎩ First dose:
Second dose: Equip FT
Six week interval
Equip FT
5 month interval
1st Booster Equip F
12-15 months interval
2nd Booster Equip F
3rd Booster Equip FT
and thereafter, booster doses of Equip FT or F so that the interval between the F component is not more than 15 months and the interval between the T component is not more than 36 months.
Note
The routine practice of administering booster doses annually may remain the most convenient, even though protection against equine influenza has been demonstrated by challenge studies 15 months following the third vaccination. No field challenge studies have been carried out prior to the third vaccination; instead efficacy was evaluated by serology which showed titres equivalent to those found in horses protected against challenge at 15 months.
Equip FT has been shown to be safe in 3-4 month old foals. However, the efficacy of active immunisation of young foals against equine influenza will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam; adequacy of colostral intake by the foal, etc. Only once maternally derived antibodies have fallen below protective levels can optimum efficacy of vaccination be assured.
|
|
Contra-indications, warnings, etc
Avoid stress when vaccinating heavily pregnant mares, since it is recognised that there is always an inherent risk in these procedures at this time.
Only healthy horses should be vaccinated.
Horses which have received immuno-suppressive drugs, e.g. glucocorticoids, should not be vaccinated until an interval of at least four weeks has elapsed.
The tetanus component of Equip FT is highly purified by a specific immunological process that should ensure that reactivity is extremely unlikely. However, as with all vaccines occasional hyper-sensitivity reactions may occur. In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously (e.g. betamethasone sodium phosphate) or adrenalin intramuscularly.
A small proportion of animals may exhibit a reaction to vaccination. This may be manifest by a mild, transient rise in temperature, typically 9-12 hours post vaccination, or a small, soft local swelling at the injection site. Both conditions are shown to have resolved the day following vaccination and are considered to be insignificant.
Keep out of reach of children.
For animal treatment only.
Pharmaceutical precautions
Store between +2° and +8°C. Protect from light. Do not freeze.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
10×2 ml doses.
Further information
In any animal population there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine together with the animal's ability to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, the presence of maternally derived antibodies, nutritional status, concurrent drug therapy and stress.
Marketing authorisation number
Vm 00201/4211
|
|
|
